for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  The Tan Sheet
   Full-text available via subscription Subscription journal
   ISSN (Print) 1530-1206
   Published by Informa plc Homepage  [13 journals]
  • Bayer, Chattem Sneeze At NAD Decision On Claritin And
           Nasacort Comparison
    • Abstract: NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
      PubDate: Fri, 24 Apr 2015 00:05:02 -040
  • BMPEA Is A Misbranding Issue For FDA, While Critics Ask Other Questions
    • Abstract: The agency issues warning letters to five companies addressing a total of eight products with labels listing beta-methylphenethylamine as a dietary ingredient, including two with labels identifying the source as the botanical acacia rigidula.
      PubDate: Thu, 23 Apr 2015 13:40:00 -040
  • ‘Distressing’ Substantiation Trends Tighten FTC Supplement
           Claim Enforcement
    • Abstract: FTC tightens requirements for claims substantiation due to fraud in studies and peer reviews, but its changes are not “monumental,” says Division of Advertising Practice official Richard Cleland. FTC likely will find it necessary to ask more supplement or nutritional product firms to conduct RCTs to support marketing claims, he adds.
      PubDate: Thu, 23 Apr 2015 00:05:01 -040
  • Industry Roundup: Prestige Brands CEO Change; Mucinex
    • Abstract: Mannelly leaves, Lombardi moves up at Prestige; and Drug Facts mislabeling prompts RB recall.
      PubDate: Thu, 23 Apr 2015 00:00:08 -040
  • Perrigo Counts 32 Billion Reasons To Reject Mylan Acquisition Offer
    • Abstract: In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.
      PubDate: Wed, 22 Apr 2015 00:05:00 -040
  • CFSAN ‘Culture’ Could Change With Director Mayne’s Staff
    • Abstract: CFSAN Director Susan Mayne says recruitment to fill vacant spots and replace soon-to-retire employees are critical. Industry stakeholders advise her to change the center’s “culture” with her staffing choices and to finish “long-pending initiatives” such as publishing agency guidance on “natural” label claims.
      PubDate: Wed, 22 Apr 2015 00:00:03 -040
  • FDA’s Homeopathic Regulation Clock Could Be Ticking Toward Change
    • Abstract: CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. “It’s time for an update. It’s time to look at how we regulate this class of products,” she says to open a public hearing.
      PubDate: Tue, 21 Apr 2015 00:00:03 -040
  • Industry Roundup: FDA Investigation Prompts Criminal Charges Against
           Supplement Marketer
    • Abstract: Watson opens supplement ingredient database; FTC shuts down melanoma app marketer; Amway’s Nutrilite wins halal award; more news in brief.
      PubDate: Mon, 20 Apr 2015 00:03:51 -040
  • Supplement GMP Compliance Means Staying On Top Of Reasons For Consumer
    • Abstract: Consumers have a new reason to doubt supplement safety “every single day,” says Lisa Thomas, general manager of NSF’s Certified for Sport program. More NSF clients are correcting GMP problems after an initial audit, “a really good thing because nobody likes to tell you to do something and then have to tell you again, especially the FDA,” she says.
      PubDate: Mon, 20 Apr 2015 00:03:44 -040
  • Executive Decisions Roundup: NBTY VPs To Lead Brand Growth
    • Abstract: NBTY names VPs to lead brand growth; and ASN science award winners.
      PubDate: Mon, 20 Apr 2015 00:03:29 -040
  • Weekly Trademark Review April 14, 2015
    • Abstract: OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
      PubDate: Mon, 20 Apr 2015 00:03:16 -040
  • Key To Growing Probiotic Sales: Talk Benefits, Not Bacteria
    • Abstract: Emphasize probiotics’ benefits rather than touting research supporting claims or using the technical terms linked to bacteria strains, says Mintel’s Lynn Dornblaser. P&G.’s Meta line capitalizes on consumers’ growing affinity for probiotics with the right approach to promote the brand.
      PubDate: Mon, 20 Apr 2015 00:01:13 -040
  • P&G CEO Lafley Could Follow Divested Brands Out The Door
    • Abstract: A.G. Lafley is expected to remain P&G chairman after stepping down as CEO as soon as this summer, according to recent reports.
      PubDate: Mon, 20 Apr 2015 00:00:50 -040
  • Degree MotionSense
           ‘Superior Protection’ Claims Idled In NAD Review
    • Abstract: Higher fragrance content does not equal a more “protective” antiperspirant, the National Advertising Division says in a decision resolving dispute between Degree marketer Unilever and competitor P&G. Flaws in Unilever’s testing design contributed to the recommendation to discontinue or modify the challenged ads.
      PubDate: Fri, 17 Apr 2015 00:00:09 -040
  • Premixed Micronutrients Deliver Recipe For Better Fortified Supplements
    • Abstract: The trend for fortified supplements, beverages and foods could steer more manufacturers to use premixed micronutrients, says Watson’s Alice Wilkinson in a webinar. Outsourcing nutrient premixes provides better product consistency and reduces the risk of incorrectly weighing separate ingredients.
      PubDate: Fri, 17 Apr 2015 00:00:02 -040
  • Homeopathic Regulation Critics Will Swing For Change Against Industry
           Stalwarts At FDA Hearing
    • Abstract: In addition to marketers and trade groups, Gary Yingling, a former FDA counsel involved in the agency’s decision to omit homeopathics from the OTC drug review, will make a presentation at a public hearing April 20-21. FDA’s current approach as “a rational framework,” CHPA says.
      PubDate: Thu, 16 Apr 2015 00:00:02 -040
  • Consent Decree Tempers J&J Consumer Outlook Even As Remediation
    • Abstract: CFO Dominic Caruso says the firm is more consistent with distributing previously recalled OTCs. U.S.
      PubDate: Wed, 15 Apr 2015 00:00:03 -040
  • Mylan Files Regulatory Notifications For Perrigo Takeover Offer
    • Abstract: Mylan files notifications with FTC and DoJ required under U.S. antitrust laws. Mylan Chairman Robert says the filing is an “important step in our ongoing determination to make this compelling proposed combination a reality.”
      PubDate: Tue, 14 Apr 2015 00:00:05 -040
  • A Day In FDA Supplement Industry Regulation: Track Spiked Product, Oversee
           Court-Ordered Recall
    • Abstract: FDA identifies a product marketed as a supplement but labeled as containing anabolic steroids and linked to three adverse event reports about “serious liver injury,” and also notes the recall of nearly 150 supplements by a firm shut down in a consent decree made after repeated GMP violations.
      PubDate: Tue, 14 Apr 2015 00:00:03 -040
  • $25 Million ‘Pure Fiction’ In Natrol Price Tag Made Real
    • Abstract: Natrol owner Aurobindo asks a bankruptcy court for an order before previous owner Plethico Pharmaceuticals agrees to pay close to the price of a phantom engineering contract Plethico claimed as a debt. Aurobindo alleged Plethico sold Natrol to prevent creditors from uncovering the sham.
      PubDate: Mon, 13 Apr 2015 00:02:34 -040
  • FDA Speaks Loudly On Approved Claims Language In Post Foods Warning
    • Abstract: Similar claims likely are made for products marketed by others firms of various sizes, but a single warning letter to a manufacturer the size of Post Food speaks louder than similar letters to numerous smaller companies.
      PubDate: Mon, 13 Apr 2015 00:02:28 -040
  • GNC Targets ‘Consumer Trust’ In N.Y. Agreement, But Industry
           Has Same Goal With Criticism
    • Abstract: As GNC explains why it accepted an agreement with N.Y. to resolve accusations about adulterated herbal supplements, industry stakeholders at Ingredient Marketplace discuss strategies on refuting those allegations and informing consumers about the quality control that is a hallmark for much of the industry.
      PubDate: Mon, 13 Apr 2015 00:02:22 -040
  • Weekly Trademark Review April 7, 2015
    • Abstract: OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
      PubDate: Mon, 13 Apr 2015 00:02:11 -040
  • Executive Decisions Roundup
    • Abstract: Hamburg joins IoM as foreign secretary; more people news in brief.
      PubDate: Mon, 13 Apr 2015 00:01:06 -040
  • Mylan Courts Perrigo In $30 Billion Bid To Build Generic Drug Powerhouse
    • Abstract: Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
      PubDate: Thu, 09 Apr 2015 00:00:22 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015